SQ-LIP-000020 · v1.2 (archived) · View current version →
How does lipedema affect quality of life, depression, and anxiety in affected patients?
Also asked as
- What impact does lipedema have on the wellbeing, depression, and anxiety levels of people who have it?
- In patients with lipedema, what are the effects on quality of life and on symptoms of depression and anxiety?
- lipedema effects quality of life depression anxiety patients
- To what extent does living with lipedema influence mental health, including depression and anxiety, and overall quality of life?
Based on currently indexed evidence, lipedema is consistently associated with reduced quality of life and elevated depressive and anxiety symptoms, though the entire evidence base is observational (cross-sectional studies and one scoping review) and graded low-to-moderate, so causal and magnitude inferences remain tentative. For quality of life, multiple cross-sectional cohorts report scores below general-population norms across WHOQOL-BREF, SF-36, EQ-5D-3L and RAND-36 instruments (e.g. WHOQOL-BREF psychological ~46 and physical ~45-51; SF-36 total 57.4/100; EQ-5D-3L 66.1 vs 85 Dutch population), with the psychological domain often most affected (SCR-LIP-000167, -000170, -000171, -000178). For depression, indexed studies report a high but variable burden: PHQ-9 means around 10-12 with 50-59% scoring >=10 in several cohorts, self-reported depression 43.6% vs 18.5% in BMI/age/sex-matched controls, and depression prevalence of 22.7-42% in the scoping review (SCR-LIP-000167, -000169, -000170, -000175). For anxiety, available studies report markedly elevated symptoms versus healthy controls, including after BMI adjustment in a small case-control study (HAM-A 27.6 vs 5.0) (SCR-LIP-000172, -000176). Quality of life appears strongly linked to mood and symptom burden: depression severity, appearance-related distress, lower mobility, pain, symptom severity and health-related stigma independently predict or correlate with worse QoL (regression models explaining 23.5-73% of QoL variance; QoL–depression r up to -0.75) (SCR-LIP-000170, -000171, -000173, -000174). An important refinement (moderate-grade) is that when lipedema patients are compared specifically with overweight/obese women rather than healthy or general-population controls, disability remains significantly worse after BMI adjustment, but depression (BDI-II, HADS-D) and anxiety (HADS-A) show NO significant difference, suggesting some of the mood burden attributed to lipedema may overlap with that of obesity (SCR-LIP-000177). Comorbidities and correlates flagged in lower-grade studies include fibromyalgia (associated with higher anxiety/depression and lower QoL), longer disease duration, higher BMI, and low serum vitamin D (SCR-LIP-000168, -000175, -000176).
⚙ AI consolidation: Claude Opus 4.8 · openrouter · 2026-05-31 — evidence-bounded; the AI does not opine
Knowledge freshness = share of the 12 indexed evidence sources from the last 5 years (newest 2025, oldest 2018) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
Answer recompiled after human curation of the claim set.
Supporting claims
- SCR-LIP-000167 supporting
In a cross-sectional study of 43 Czech women with lipedema, 50.9% had moderate-to-severe depressive symptoms (PHQ-9 >=10) and WHOQOL-BREF scores were low across domains (psychological 46.3, physical 50.8), with the psychological domain most affected; specific physical symptoms (shortness of breath, muscle stiffness, appetite problems, fatigue, numbness) were significantly associated with depression severity.
Mental and physical health burden and quality of life in Czech women with lipedema — Kunzová et al. (2025) - SCR-LIP-000168 supporting
In a cross-sectional study of 354 women with lipedema, 35% met FMS criteria, and those with comorbid FMS had significantly higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) scores and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) quality-of-life scores (all p<0.001).
Prevalence of Fibromyalgia Syndrome in Women with Lipedema and Its Effect on Anxiety, Depression, and Quality of Life — Cagliyan Turk et al. (2024) - SCR-LIP-000169 supporting
In a study comparing lipedema patients with population controls matched for sex, age and BMI, lipedema patients reported worse self-rated general health, higher rates of self-reported depression (43.6% vs 18.5%, p=0.001) with PHQ-8 depressive symptoms in 89.7% versus 39.3% of controls, more severe pain and pain-related disability, fewer close social contacts, and a strong positive correlation between pain severity and depressive symptoms (rho=0.612, p<0.001).
Health Implications of Lipedema: Analysis of Patient Questionnaires and Population-Based Matched Controls — Kempa et al. (2024) - SCR-LIP-000170 supporting
In a survey of 98 Polish women with lipedema, all WHOQOL-BREF domains scored below general-population values (physical health 45.4, psychological 46.3, social relationships 50.4, environment 49.6 on 0-100), 59.2% had PHQ-9 scores >=10 indicating possible depression (mean PHQ-9 12.2), and core lipedema symptoms (Factor 1: leg heaviness, joint/tissue/muscle pain, swelling, stiffness) were the only significant predictor of worse quality of life (beta=-0.345, p=0.004, model explaining 23.5% of variance).
Quality of life, its factors, and sociodemographic characteristics of Polish women with lipedema — Dudek et al. (2021) - SCR-LIP-000171 supporting
In this scoping review, lipedema patients showed reduced quality of life (EQ-5D-3L 66.1 vs 85 in the Dutch population; WHOQOL-BREF physical/mental domains below midpoint), depression prevalence of 22.7%-42%, 51.1% with mental disorders, and QoL strongly correlated with depression severity (r=-0.75).
Lipoedema as a Social Problem. A Scoping Review — Czerwińska et al. (2021) - SCR-LIP-000172 supporting
In an observational study of 26 females with lipedema versus healthy controls, lipedema patients showed markedly higher emotion regulation difficulties (DERS total 135.69±13.12 vs 53.00±9.03) and anxiety (HAM-A 27.62±8.98 vs 4.96±2.51), with all group differences remaining significant after adjusting for BMI via ANCOVA (DERS total F(1,49)=582.95, p<0.001; HAM-A F(1,49)=123.10, p<0.001).
The Difficulties in Emotional Regulation among a Cohort of Females with Lipedema — Al-Wardat et al. (2022) - SCR-LIP-000173 supporting
In 329 women with lipedema, lower quality of life (WHOQOL-BREF) was independently predicted by higher depression (PHQ-9 β=-0.36), higher appearance-related distress (DAS-24 β=-0.29), lower mobility (β=0.27) and higher symptom severity, with the final regression model explaining 73% of QoL variance and mean PHQ-9 of 11.87 indicating minor depression.
Depression and appearance-related distress in functioning with lipedema — Dudek et al. (2018) - SCR-LIP-000174 supporting
In a cross-sectional survey of 245 women with lipedema, health-related stigma was significantly higher than in an age-matched general female population (Distress 49.5 vs 17.1–28.7; 65% with moderate/severe distress) and correlated negatively with all RAND-36 quality-of-life domains (strongest for social functioning r=−0.54 and emotional well-being r=−0.50), while greater perceived social support correlated positively with HRQoL.
Health-related stigma, perceived social support, and their role in quality of life among women with lipedema — Falck et al. (2025) - SCR-LIP-000175 supporting
In a cross-sectional study of 37 women with lipedema versus 36 with lymphedema, lipedema patients showed moderate depression (PHQ-9 mean 10.4) and impaired global quality of life (LYMQOL-Leg 5.47) comparable to lymphedema patients, while lymphedema patients had worse functional status and life satisfaction; in lipedema, longer disease duration correlated with PHQ-9 (r=-0.415, p=0.028) and BMI correlated with functional impairment.
The Comparative Evaluation of Depression, Life Satisfaction, and Quality of Life Between Female Patients with Lipedema and Lymphedema — Yaman et al. (2025) - SCR-LIP-000176 supporting
In a cross-sectional cohort of 40 lipedema patients, 87.5% showed severe/high depression risk (mean HAM-D 25.39) and 92.5% showed severe/high anxiety risk (mean HAM-A 23.45), with serum vitamin D inversely correlated with depression (adjusted r=-0.580, p<0.001) and anxiety (adjusted r=-0.489, p=0.002), and BMI positively correlated with both depression (r=0.560) and anxiety (r=0.511).
The association between serum vitamin D and mood disorders in a cohort of lipedema patients — Al-Wardat et al. (2021) - SCR-LIP-000178 supporting
In 44 women with lipedema, median total SF-36 quality of life was 57.4/100 (lowest domains: general health 35, pain 47.5, social functioning 50, energy/fatigue 45), below historical healthy Polish population (61.6) and a prior lipedema cohort (59.3), and SF-36 scores did not differ by BMI or WHtR strata.
Examining the characteristic features of lipedema and the usefulness of BMI and WHtR in clinical evaluation — Czerwińska et al. (2025)
Contradictory claims
- None indexed yet.
Refining / context
- SCR-LIP-000177 refines
Compared with overweight/obese women, women with lipedema showed greater disability (WHO-DAS II domains for mobility, household activities, and social participation remained significantly worse after robust BMI adjustment, e.g. social participation Z=3.15, p=0.002; days with difficulties Z=4.13, p<0.001), but showed NO significant differences in depression (BDI-II median 11 vs 8, p=0.130; HADS-D p=0.474) or anxiety (HADS-A 9.16 vs 8.10, p=0.162), before or after BMI adjustment.
Disability and emotional symptoms in women with lipedema: A comparison with overweight/obese women — Chachaj et al. (2024)
Major uncertainty
The central unresolved issue is causal attribution: nearly all evidence is cross-sectional and confounded by obesity, and the strongest comparison against an appropriate control group (overweight/obese women) found no significant difference in depression or anxiety after BMI adjustment (SCR-LIP-000177), directly conflicting with small healthy-control studies reporting large BMI-adjusted differences (SCR-LIP-000172). It remains unclear how much of the observed mood and QoL burden is specific to lipedema versus shared with obesity, pain, or stigma; no longitudinal or interventional data establish directionality, and reported depression/anxiety magnitudes vary widely across small cohorts with unknown risk of bias.
Version history
- SQ-LIP-000020 · v1.2 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000020 · v1.1 — 2026-05-31 — This update established the first answer for this question by indexing 12 observational studies/reviews showing reduced quality of life and elevated depression/anxiety in lipedema, while adding a key moderate-grade refinement that mood differences may disappear when comparing against BMI-matched overweight/obese controls. · view this version
- SQ-LIP-000020 · v1.0 — 2026-05-31 — Question created (promoted from SQ-LIP-D000005). · view this version
Key references
DOI:10.3389/fgwh.2025.1629077 · DOI:10.1089/lrb.2023.0038 · DOI:10.3390/life14030295 · DOI:10.1186/s12905-021-01174-y · DOI:10.3390/ijerph181910223 · DOI:10.3390/ijerph192013679 · DOI:10.1080/13548506.2018.1459750 · DOI:10.1080/07399332.2025.2499487 · DOI:10.1089/lrb.2024.0117 · DOI:10.1515/hmbci-2021-0027 · DOI:10.17219/acem/181146 · DOI:10.1186/s12905-025-03834-9